{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:48:11Z","timestamp":1771307291311,"version":"3.50.1"},"reference-count":72,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: Following renal transplantation, infection with cytomegalovirus (CMV) is a common and feared complication. mTOR-inhibitor (mTOR-I) treatment, either alone or in combination with calcineurininhibitors (CNIs), significantly reduces the CMV incidence after organ transplantation. As of now, there is no information on which mTOR-I, sirolimus (SIR) or everolimus (ERL), has a stronger anti-CMV effect. (2) Methods: The current literature was searched for prospective randomized controlled trials in renal transplantation. There were 1164 trials screened, of which 27 could be included (11,655 pts.). We performed a network meta-analysis to analyze the relative risk of different types of mTOR-I treatment on CMV infection 12 months after transplantation compared to CNI treatment. (3) Results: Four different types of mTOR-I treatment were analyzed in network meta-analyses\u2014SIR mono, ERL mono, SIR with CNI, ERL with CNI. The mTOR-I treatment with the strongest anti-CMV effect compared to a regular CNI treatment was ERL in combination with a CNI (relative risk (RR) 0.27, confidence interval (CI) 0.22\u20130.32, p &lt; 0.0001). The other mTOR-I therapy groups showed a slightly decreased anti-CMV efficacy (SIR monotherapy (mono): RR 0.35, CI 0.22\u20130.57, p &lt; 0.001; SIR with CNI: RR 0.43, CI 0.29\u20130.64, p &lt; 0.0001; ERL mono: RR 0.46, CI 0.22\u20130.93, p = 0.031). (4) Conclusions: The anti-CMV effect of both mTOR-Is (SRL and ERL) is highly effective, irrespective of the combination with other immunosuppressive drugs. Certain differences with respect to the potency against the CMV could be found between SRL and ERL. Data gained from this analysis seem to support that a combination of ERL and CNI has the most potent anti-CMV efficacy.<\/jats:p>","DOI":"10.3390\/jcm11144216","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T11:22:24Z","timestamp":1658316144000},"page":"4216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Sirolimus vs. Everolimus on CMV-Infections after Kidney Transplantation\u2014A Network Meta-Analysis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5298-8901","authenticated-orcid":false,"given":"Sebastian","family":"Wolf","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital Augsburg, 86156 Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-5390","authenticated-orcid":false,"given":"Verena S.","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Institute for Medical Information Processing Biometry and Epidemiology (IBE), Ludwig-Maximilian\u2019s University, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-3027","authenticated-orcid":false,"given":"Florian","family":"Sommer","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital Augsburg, 86156 Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schrempf","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital Augsburg, 86156 Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilian\u2019s University, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Ryll","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilian\u2019s University, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilian\u2019s University, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-1368","authenticated-orcid":false,"given":"Matthias","family":"Ilmer","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilian\u2019s University, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilian\u2019s University, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-3913","authenticated-orcid":false,"given":"Joachim","family":"Andrassy","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilian\u2019s University, 81377 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1600-6143.2009.02887.x","article-title":"Practice ASTIDCo. Introduction: Infection in solid organ transplant recipients","volume":"9","author":"Fishman","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S701","DOI":"10.1093\/clinids\/12.Supplement_7.S701","article-title":"Epidemiology of cytomegalovirus infections","volume":"12","author":"Ho","year":"1990","journal-title":"Rev. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","article-title":"Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials","volume":"365","author":"Hodson","year":"2005","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1600-6143.2008.02369.x","article-title":"Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review","volume":"8","author":"Sun","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e13267","DOI":"10.1111\/tid.13267","article-title":"Infections after kidney transplantation: A comparison of mTOR-Is and CNIs as basic immunosuppressants. A systematic review and meta-analysis","volume":"22","author":"Wolf","year":"2020","journal-title":"Transpl. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_10","unstructured":"(2022, May 14). Network Meta-Analysis Using Freuquentist Methods. Available online: https:\/\/cran.r-project.org\/web\/packages\/netmeta\/netmeta.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_13","unstructured":"Julian, P.T., and Higgins, S.G. (2022, May 14). Cochrane Handbook for Systematic Reviews of Interventions 2008. Available online: https:\/\/handbook-5-1.cochrane.org."},{"key":"ref_14","unstructured":"Doug Altman, D.A., Ralf, B., Catey, B., Marion, C., Mike, C., Jon, D., Simon, G., Julian, H., Nathan, P., and Simon, T. (2011). Chapter 16: Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions Version 510, The Cochrane Collaboration. Available online: www.handbook.cochrane.org."},{"key":"ref_15","first-page":"377","article-title":"The quality of reporting of randomized controlled trials in solid organ transplantation","volume":"22","author":"Pengel","year":"2009","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"Buchler","year":"2007","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1600-6143.2012.04036.x","article-title":"Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: The SPIESSER study","volume":"12","author":"Lebranchu","year":"2012","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_18","first-page":"41","article-title":"Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation","volume":"29","author":"Gatault","year":"2016","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1681\/ASN.2011010006","article-title":"Randomized trial of immunosuppressive regimens in renal transplantation","volume":"22","author":"Guerra","year":"2011","journal-title":"J. Am. Soc. Nephrol"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/TP.0b013e318160d3c9","article-title":"Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor","volume":"85","author":"Durrbach","year":"2008","journal-title":"Transplantation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181db09e4","article-title":"Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids","volume":"89","author":"Glotz","year":"2010","journal-title":"Transplantation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"ref_27","first-page":"416","article-title":"Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36months after transplantation","volume":"25","author":"Guba","year":"2012","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ndt\/gfx093","article-title":"De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: A multicentre, open-label, randomized, controlled, non-inferiority trial","volume":"32","author":"Huh","year":"2017","journal-title":"Nephrol Dial Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2005.00885.x","article-title":"A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis","volume":"5","author":"Kandaswamy","year":"2005","journal-title":"Am. J. Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/ajt.12166","article-title":"Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation","volume":"13","author":"Suszynski","year":"2013","journal-title":"Am. J. Transpl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am. J. Transpl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/j.1600-6143.2009.02803.x","article-title":"Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus","volume":"9","author":"Servais","year":"2009","journal-title":"Am. J. Transpl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1600-6143.2011.03637.x","article-title":"Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study","volume":"11","author":"Lebranchu","year":"2011","journal-title":"Am. J. Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/tri.12878","article-title":"ADHERE: Randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus","volume":"30","author":"Rummo","year":"2017","journal-title":"Transpl. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/tri.13527","article-title":"Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients","volume":"33","author":"Rummo","year":"2020","journal-title":"Transpl. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0012.2007.00756.x","article-title":"Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen","volume":"22","author":"Sampaio","year":"2008","journal-title":"Clin. Transplant."},{"key":"ref_37","first-page":"731426","article-title":"Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation","volume":"2010","author":"Bustamante","year":"2010","journal-title":"J. Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-6143.2005.01193.x","article-title":"Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study","volume":"6","author":"Vitko","year":"2006","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_39","first-page":"14","article-title":"Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: A randomised trial","volume":"76","author":"Bouamar","year":"2018","journal-title":"Neth. J. Med."},{"key":"ref_40","first-page":"1060","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: A multicentre, randomized trial","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_41","first-page":"302","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.transproceed.2016.03.048","article-title":"Pilot Randomized Trial of Tacrolimus\/Everolimus vs Tacrolimus\/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center","volume":"48","author":"Ciancio","year":"2016","journal-title":"Transpl. Proc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/tri.13478","article-title":"Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor","volume":"32","author":"Ferreira","year":"2019","journal-title":"Transpl. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation","volume":"12","author":"Mjornstedt","year":"2012","journal-title":"Am. J. Transpl."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/ctr.12565","article-title":"Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial","volume":"29","author":"Murbraech","year":"2015","journal-title":"Clin. Transpl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J. Am. Soc. Nephrol"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data","volume":"17","author":"Qazi","year":"2017","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Shihab, F., Qazi, Y., Mulgaonkar, S., McCague, K., Patel, D., Peddi, V.R., and Shaffer, D. (2017). Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg.","DOI":"10.1111\/ajt.14215"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13679","DOI":"10.1111\/ctr.13679","article-title":"Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients","volume":"33","author":"Taber","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transpl. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Cibrik","year":"2010","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses","volume":"15","author":"Felipe","year":"2015","journal-title":"Am. J. Transpl."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4049\/jimmunol.182.1.477","article-title":"Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor","volume":"182","author":"Frascaroli","year":"2009","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1128\/JVI.02733-09","article-title":"Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication","volume":"84","author":"Moorman","year":"2010","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"ref_60","first-page":"CD004290","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"2","author":"Webster","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","article-title":"The multifunctional role of mTOR in innate immunity: Implications for transplant immunity","volume":"9","author":"Saemann","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1128\/JVI.02421-05","article-title":"Human cytomegalovirus subverts the functions of monocytes, impairing chemokine-mediated migration and leukocyte recruitment","volume":"80","author":"Frascaroli","year":"2006","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1600-6143.2012.04002.x","article-title":"CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages","volume":"12","author":"Poglitsch","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood-2010-09-310888","article-title":"Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells","volume":"117","author":"Weichhart","year":"2011","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature03205","article-title":"Regulation of cap-dependent translation by eIF4E inhibitory proteins","volume":"433","author":"Richter","year":"2005","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1016\/j.transproceed.2008.09.049","article-title":"Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation","volume":"40","author":"Moro","year":"2008","journal-title":"Transplant. Proc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5414\/CNP63080","article-title":"Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus","volume":"63","author":"Kamar","year":"2005","journal-title":"Clin. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"E401","DOI":"10.1111\/j.1399-0012.2011.01446.x","article-title":"Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen","volume":"25","author":"Carvalho","year":"2011","journal-title":"Clin. Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","article-title":"Comparative analysis of adverse events requiring suspension of mTOR inhibitors: Everolimus versus sirolimus","volume":"42","author":"Ruiz","year":"2010","journal-title":"Transplant. Proc."},{"key":"ref_71","first-page":"279","article-title":"Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: Defining the role of calcineurin inhibitors","volume":"17","author":"Nashan","year":"2004","journal-title":"Transpl. Int. Off. J. Eur. Soc. Organ Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","article-title":"New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: Possible consequences for therapeutic drug monitoring in solid organ transplantation","volume":"31","author":"Naesens","year":"2009","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/4216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:54:45Z","timestamp":1760140485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/4216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":72,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11144216"],"URL":"https:\/\/doi.org\/10.3390\/jcm11144216","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]}}}